Aktienanalyse zu CNS Pharmaceuticals Inc (CNSP)CNSPCNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CNS Pharmaceuticals is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $3.94, with an RSI of 29.263 indicating oversold conditions. The company reported a net loss of approximately $4.937 million in Q1 2026, which is a 14.7% increase from the previous year's loss. Additionally, the stock has decreased by 39.29% over the past year, reflecting ongoing financial struggles and lack of revenue, which raises concerns about its long-term viability.